ReviewCell reports2025
Two decades of FFAR4 biology: From nutrient sensing to therapeutic targeting.
Review in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Free fatty acid receptor 4 (FFAR4; also known as GPR120) serves as a key lipid-sensing G-protein-coupled receptor that mediates the physiological actions of long-chain fatty acids, particularly omega-3 polyunsaturated fatty acids. Over the past two decades, studies of FFAR4 have revealed its pivotal role in metabolic regulation, inflammation resolution, and energy balance. This review integrates recent advances from structural biology, physiology, and translational research to provide an updated framework of FFAR4 biology. In particular, we highlight new cryo-electron microscopy-based insights into receptor activation and ligand recognition; the expanding roles of FFAR4 in non-metabolic systems, such as the central nervous system and kidney; and recent progress in the clinical development of selective FFAR4 agonists. By bridging molecular mechanisms with therapeutic translation, this review offers a comprehensive perspective on FFAR4's functions in health and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.